Results 1 to 10 of about 88,264 (269)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients [PDF]
Haematologica, 2016 In 2014, ibrutinib was made available for relapsed/refractory chronic lymphocytic leukemia patients. The UK Chronic Lymphocytic Leukaemia Forum collected data from UK/Ireland patients with a minimum of 1 year follow-up with pre-planned primary endpoints;
UK CLL Forum
doaj +2 more sources
Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison. [PDF]
J Comp Eff ResAim: Fludarabine, cyclophosphamide and rituximab (FCR) is a first-line therapy for fit treatment-naive patients with chronic lymphocytic leukemia (CLL); however, its hematotoxicity and related infections necessitate more efficacious, safer treatments ...
Munir T +6 more
europepmc +2 more sources
CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis
Experimental Hematology & Oncology, 2022 Objective Circular RNAs (circRNAs) play a critical role in the modulation of tumor metabolism. However, the expression patterns and metabolic function of circRNAs in chronic lymphocytic leukemia (CLL) remain largely unknown. This study aimed to elucidate
Zijuan Wu +13 more
doaj +1 more source
Molecular Oncology, 2022 Ibrutinib exerts promising anticancer effects in chronic lymphocytic leukaemia (CLL). However, acquired resistance occurs during treatment, necessitating the exploration of underlying mechanisms.
Zijuan Wu +15 more
doaj +1 more source
Clinical and Translational Medicine, 2022 Background Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma. Histone deacetylase inhibitors (HDACis) have been widely applied in multiple tumours, but the expected efficacy was not observed in DLBCL.
Luqiao Wang +11 more
doaj +1 more source
Annals of Global Health, 2021 Background: Various multifactorial elements may contribute toward the urban and rural disparities in cardiovascular disease (CVD) risk, particularly among patients with psychiatric diseases.
Juan Pablo Forero +6 more
doaj +1 more source
Venetoclax inhibits autophagy in chronic lymphocytic leukemia cells
Autophagy Reports, 2023 Venetoclax (VCX) is a BCL2 inhibitor approved for treating B cell-derived leukemia, including chronic lymphocytic leukemia (CLL). VCX’s role in apoptosis induction is well-defined, whereas its other mechanistic roles need to be clarified. Autophagy is an
Yongqiang Chen +6 more
doaj +1 more source
Chronic lymphocytic leukaemia trends and features at a tertiary hospital in South Africa (2011–2016)
South African Journal of Oncology, 2021 Background: Chronic lymphocytic leukaemia (CLL) is a common lymphoproliferative disorder in developed countries. However, this condition is rare in Africa and there is a paucity of information on CLL, specifically on the continent.
Fungai Musaigwa +3 more
doaj +1 more source
Ciencia y Tecnología Agropecuaria, 1998 A partir del análisis de muestras palinológicas de Carate 25, planicie aluvial del bajo río San Jorge ubicada en el municipio de San Marcos (Sucre, Colombia), de las investigacion es arqueológicas realizadas en dicha región y de los datos cronológicos ...
Luisa Fernanda Herrera +1 more
doaj +1 more source
Assessment of miR-150-5 p as diagnostic and prognostic markers of B- chronic Lymphocytic Leukemia in chronic hepatitis C [PDF]
African Journal of Gastroenterology and Hepatology, 2023 Aims: the current study aimed to investigate the role of miR-150-5 p expression as a diagnostic and prognostic marker of B- CLL among Egyptian patients with chronic hepatitis C and its impact on risk stratification and response to therapy.Patients ...
Nearmeen Rashad +6 more
doaj +1 more source